Should end-of-therapy echocardiograms be obtained for AYA patients with sarcomas who have received high-dose anthracyclines?
At what frequency and for how long should echos be monitored?
Answer from: at Academic Institution
Exposure to anthracyclines will predispose cancer survivors to cardiomyopathy in a dose dependent manner, both alone and in combination with radiation therapy to the chest. While cumulative doses > 250 mg/m2 are associated with increasing risk of cardiomyopathy, lower doses have been implicated a...
Sign in or Register to read more